Vasopressor Choice in Septic Shock With a Failing Right Ventricle
A single patient with septic shock layered onto three years of Group 3 pulmonary hypertension. The sepsis protocol has a first-line answer; his right ventricle, which is the thing most likely to kill him tonight, was never in the population that answer came from.
W.G. spent almost forty years running his own auto repair shop before severe COPD forced him to sell it to a longtime employee six years ago, and has been on 3 liters of home oxygen and followed for Group 3 pulmonary hypertension — pulmonary hypertension secondary to his chronic lung disease — for the past three years, since a right heart catheterization confirmed a mean pulmonary artery pressure of 38 mmHg after two years of progressive exertional breathlessness. He has also been on a low-dose diuretic for the past year for mild lower-extremity edema, itself a sign of the chronic right-heart strain now compounding with tonight's acute illness. He came in today with two days of fever, jaundice, and worsening confusion; imaging confirmed ascending cholangitis with a dilated common bile duct, and by the time source control with an urgent ERCP was being arranged he was in septic shock, hypotensive despite fluids and now on a moderate dose of norepinephrine.
His echocardiogram tonight shows a moderately dilated, hypokinetic right ventricle — his catheterized mean PA pressure of 38 mmHg was a ventricle already working against a doubled afterload for three years, and tonight's sepsis has added acute strain to a chamber with no reserve left to recruit. That changes what the team is actually worried about: in a patient with this degree of chronic right-heart disease, a decompensating right ventricle is often the more immediate threat to survival than the septic source itself, since RV failure can proceed to cardiac arrest faster than an infection an antibiotic and a drain can eventually control. He needs vasopressor support and nobody disputes it. What nobody in the room can point to is a randomized trial run in patients like him: VASST compared vasopressin against norepinephrine in septic shock and came out neutral overall, and it did not enroll for chronic right-heart disease. The ERCP suite is being readied upstairs, and the drug going into his line in the next few minutes will be chosen on vascular pharmacology rather than on outcome data, because outcome data for this patient does not exist.
Which failing organ the first drug should protect
I'd start norepinephrine first-line, the way Surviving Sepsis Campaign guidance recommends for essentially every septic shock patient — it has the strongest outcome evidence as a default opening agent, and VASST, the randomized head-to-head against vasopressin, found no overall mortality difference to displace it. Its main concern in pulmonary hypertension, dose-dependent pulmonary vasoconstriction, is real but modest at the doses usually needed to restore MAP. I wouldn't deviate from first-line evidence without a more specific reason than ‘he has some pulmonary hypertension.’
His pulmonary hypertension isn't a modest comorbidity tonight — given tonight's echo, a decompensating right ventricle is arguably the more immediate threat to his survival than the biliary source itself. Vasopressin acts through V1 receptors that are sparsely distributed in the pulmonary vasculature, so it raises systemic resistance while largely sparing pulmonary vascular resistance — the opposite of norepinephrine's dose-dependent pulmonary vasoconstriction. I'd take VASST's neutrality as telling us nothing about him rather than as an argument against: it was a general septic-shock population and didn't enroll for right-heart disease. Price's systematic review is more to the point, and it recommends low-dose vasopressin specifically for resistant vasodilatory shock in pulmonary vascular dysfunction.
The evidence for norepinephrine-first is genuinely strong, but it was mostly built in populations without his degree of chronic right-heart disease — that's exactly the population this patient isn't drawn from.
I'd argue the vasopressor choice matters less than what's missing from this conversation entirely — an inotrope. Whichever vasoconstrictor you pick, neither one fixes the actual mechanical problem: a right ventricle struggling against elevated afterload needs direct inotropic support, not just a better choice within the same vasoconstrictor category. I'd add low-dose dobutamine once his MAP tolerates it, aimed specifically at the failing RV rather than at his blood pressure number — Price's review gives that a specific recommendation for improving RV function in pulmonary vascular dysfunction, and it's the one intervention here anybody has actually studied for the problem we're describing.
Agreed: start norepinephrine first-line per standard sepsis protocol, add vasopressin early rather than waiting for high-dose norepinephrine given his known chronic pulmonary hypertension, and add low-dose dobutamine once his MAP tolerates it to support the right ventricle directly.
Not agreed:
Whether vasopressin should have been the first agent rather than added second. The pulmonologist holds that a patient with this degree of chronic pulmonary hypertension should lead with the more pulmonary-vasculature-neutral agent from the start; the critical care physician holds that deviating from norepinephrine-first as an opening move isn't justified until MAP targets are actually missed on first-line therapy. The disagreement is about sequencing, not about the regimen the team actually converged on tonight.